Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Phase 2
24
about 5.9 years
18+
1 site in TX
About this study
This trial is testing a treatment called anakinra, which is an anti-inflammatory medication, when combined with chemotherapy for people who have pancreatic adenocarcinoma. The goal is to see if adding anakinra improves outcomes for these patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Anakinra
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
anakinra
Secondary: To describe the effect of anakinra in combination with perioperative chemotherapy on the prevalence and severity of pain by monitoring patients' pain level using memorial pain assessment card (MPAC)., To determine the effect of anakinra in combination with perioperative chemotherapy on overall survival (OS) of PDAC patients. A benchmark of 24 months OS will be used to determine how many patients meet or exceed this goal., To determine the effect of anakinra in combination with perioperative chemotherapy on patients' health-related quality of life by monitoring patients using EORTC quality of life survey questionnaire (EORTC QLQ-C30)., To determine the effect of anakinra in combination with perioperative chemotherapy on response rate, To determine the effect of anakinra in combination with perioperative chemotherapy on the inflammasomes ( IL6, CRP, IL1α and IL1β) in blood and in the resected pathology specimens., To determine the effect of anakinra in combination with perioperative chemotherapy on the median disease free survival (DFS). A benchmark of 12 months DFS will be used to determine how many patients meet or exceed this goal.